Is 18F-fluorodeoxyglucose positron emission tomography in recurrent colorectal cancer a contribution to surgical decision making?

American Journal of Surgery

Volumn 180, Issue 1, 2000, Pages 1-5

  Staib, Ludger ^a   Schirrmeister, Holger ^a   Reske, Sven Norbert ^a   Beger, Hans Günther ^a  

^a UNIVERSITY OF ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER STAGING; CANCER SURGERY; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; ECHOGRAPHY; FEMALE; FOLLOW UP; HUMAN; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECURRENT CANCER; ABDOMINAL TUMOR; COLON TUMOR; COMPARATIVE STUDY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DECISION MAKING; EVALUATION; LIVER TUMOR; METASTASIS; MIDDLE AGED; PATIENT CARE PLANNING; RECTUM TUMOR; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; THORAX TUMOR; TUMOR RECURRENCE;

ABDOMINAL NEOPLASMS; ADULT; AGED; AGED, 80 AND OVER; CARCINOEMBRYONIC ANTIGEN; COLONIC NEOPLASMS; DECISION MAKING; FEMALE; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PATIENT CARE PLANNING; RADIOPHARMACEUTICALS; RECTAL NEOPLASMS; SENSITIVITY AND SPECIFICITY; THORACIC NEOPLASMS; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, X-RAY COMPUTED;

EID: 0033623134     PISSN: 00029610     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9610(00)00406-2     Document Type: Article

References (27)

1. Batzler W.U., Baumgart-Elms C., Eisinger B., et al. Krebs in Deutschland- Häufigkeiten und Trends. 1997;Fa. Braun Druck, Riegelsburg.
2. Landis S.H., Murray T., Bolden S., Wingo P.A. Cancer statistics 1999. CA-Cancer J Clin. 49:1999;8-31.
3. Tempero M., Brand R., Holdeman K., Matamoros A. New imaging techniques in colorectal cancer. Semin Oncol. 22:1995;448-471.
4. Reske S.N., Guhlmann A., Schirrmeister H. Positron-emission tomography in the diagnosis of abdominal tumors. Schweiz Med Wochenschr. 128:1998;96-108.
5. Safi F., Link K.H., Beger H.G. Is follow-up of colorectal cancer patients worthwhile? Dis Colon Rectum. 36:1993;636-644.
6. Diederichs C.G., Staib L., Glatting G., et al. FDG PET elevated plasma glucose reduces both uptake and detection rate of pancreatic malignancies . J Nucl Med. 39:1998;1030-1033.
7. Tarif der Deutschen Krankenhausgesellschaft für die Abrechnung erbrachter Leistungen (DKG-NT). 1997;W Kohlhammer Verlag, Stuttgart.
8. Sachs L. Angewandte Statistik. 1992;Springer-Verlag, Berlin.
9. StatView. 1995;Abacus Concepts, Inc, Berkeley, Calif.
10. Beets G., Penninckx F., Schiepers C., et al. Clinical value of whole-body positron emission tomography with [18F]fluorodeoxyglucose in recurrent colorectal cancer. Br J Surg. 81:1994;1666-1670.
11. Ogunbiyi O.A., Flanagan F.L., Dehdashti F., et al. Detection of recurrent and metastatic colorectal cancer comparison of positron emission tomography and computed tomography . Ann Surg Oncol. 4:1997;613-620.
12. Paulus P., Hustinx R., Daenen F., et al. Usefulness of 18FDG positron emission tomography in detection and follow-up of digestive cancers. Acta Gastroenterol Belg. 60:1997;278-280.
13. Valk P.E., Abella-Columna E., Haseman M.K., et al. Whole-body PET imaging with [18F]fluorodeoxyglucose in management of recurrent colorectal cancer. Arch Surg. 134:1999;503-511.
14. Strauss L.G., Clorius J.H., Schlag P., et al. Recurrence of colorectal tumors PET evaluation . Radiology. 170:1989;329-332.
15. Schlag P., Lehner B., Strauss L.G., et al. Scar or recurrent rectal cancer. Positron emission tomography is more helpful for diagnosis than immunoscintigraphy. Arch Surg. 124:1989;197-200.
16. Ito K., Kato T., Tadokoro M., et al. Recurrent rectal cancer and scar differentiation with PET and MR imaging . Radiology. 182:1992;549-552.
17. Schiepers C., Penninckx F., De Vadder N., et al. Contribution of PET in the diagnosis of recurrent colorectal cancer comparison with conventional imaging . Eur J Surg Oncol. 21:1995;517-522.
18. Delbeke D., Vitola J.V., Sandler M.P., et al. Staging recurrent metastatic colorectal carcinoma with PET. J Nucl Med. 38:1997;1196-1201.
19. Keogan M.T., Lowe V.J., Baker M.E., et al. Local recurrence of rectal cancer evaluation with F-18 fluorodeoxyglucose PET imaging . Abdom Imag. 22:1997;332-337.
20. Ruhlmann J., Schomburg A., Bender H., et al. Fluorodeoxyglucose whole-body positron emission tomography in colorectal cancer patients studied in routine daily practice. Dis Colon Rectum. 40:1997;1195-1204.
21. Vitola J.V., Delbeke D., Sandler M.P., et al. Positron emission tomography to stage suspected metastatic colorectal carcinoma to the liver. Am J Surg. 171:1996;21-26.
22. Fröhlich A., Diederichs C., Staib L., et al. Detection of liver metastases from pancreatic cancer using FDG PET. J Nucl Med. 40:1999;250-255.
23. Lowe V.J., Fletcher J.W., Gobar L., et al. Prospective investigation of positron emission tomography in lung nodules. J Clin Oncol. 16:1998;1075-1084.
24. Miraldi F., Vesselle H., Faulhaber P.F., et al. Elimination of artifactual accumulation of FDG in PET imaging of colorectal cancer. Clin Nucl Med. 23:1998;3-7.
25. Gordon B.A., Flanagan F.L., Dehdashti F. Whole-body positron emission tomography normal variations, pitfalls, and technical considerations . Am J Roentgenol. 169:1997;1675-1680.
26. Staib L, Braumüller H, Leeser C, et al. First report of active specific immunization in colorectal and pancreatic cancer patients with CO17-1A vaccine. Langenbecks Arch Chir Suppl I (Forumband 1998). 1998;(suppl I):53-58.
27. Flamen P., Stroobants S., Van Cutsem E., et al. Additional value of whole-body positron emission tomography with fluorine-18-2-fluoro-2-deoxy-D-glucose in recurrent colorectal cancer. J Clin Oncol. 17:1999;894-901.